Binding and Presentation of Lipid Antigens by CD1

$382,338R01FY2013AINIH

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications & trials

Paper 39062144 Paper 38629075 Paper 38477945 Paper 36263021 Paper 36091032 Paper 33483371 Paper 33310870 Paper 33296161 Paper 32463330 Paper 30881361 Paper 30323255 Paper 30085659 Paper 30076070 Paper 29576533 Paper 29458078 Paper 28401935 Paper 27390759 Paper 27195112 Paper 27166856 Paper 26496152 Paper 26306469 Paper 26157173 Paper 26078271 Paper 25314062 Paper 25255287 Paper 24965554 Paper 24762075 Paper 24412610 Paper 23530121 Paper 23382238 Paper 22995911 Paper 22652050 Paper 22174854 Paper 22110136 Paper 22065767 Paper 22006319 Paper 21964029 Paper 21804559 Paper 21666690 Paper 21425779 Paper 21376639 Paper 21361909 Paper 21245578 Paper 21179412 Paper 20539017 Paper 20529677 Paper 20462758 Paper 20083656 Paper 20061147 Paper 20015094 Paper 19949076 Paper 19945296 Paper 19816402 Paper 19620317 Paper 19563525 Paper 19538930 Paper 19506241 Paper 19481452 Paper 19468063 Paper 19369232 Paper 18779390 Paper 18586489 Paper 18538591 Paper 18308638 Paper 18272236 Paper 18180309 Paper 17896821 Paper 17483872 Paper 17442335 Paper 17276880 Paper 17237389 Paper 17071611 Paper 17015708 Paper 16920929 Paper 16675349 Paper 16585584 Paper 16323834 Paper 16083968 Paper 16009719 Paper 16002672 Paper 15728470 Paper 15722411 Paper 15710652 Paper 15661873 Paper 15466622 Paper 15304644 Paper 15228522 Paper 15039328 Paper 14991068 Paper 14688141 Paper 12882830 Paper 12878359 Paper 12761085 Paper 12626573 Paper 12580540 Paper 12492810 Paper 12471129 Paper 12077262 Paper 12047745 Paper 11938350

Abstract

DESCRIPTION (provided by applicant): T lymphocytes known as type 1 or invariant NKT cells (iNKT cells) recognize specific lipid ligands presented by the CD1d protein, and this component of the CD1-dependent immune response is highly conserved between humans and mice. Many detailed studies in mouse models have shown that iNKT cells contribute to immune responses against pathogens, elimination of malignant tumors, maintenance of immunological tolerance and prevention of autoimmune diseases. Great progress in understanding and potentially harnessing the many immunological activities of iNKT cells has been made in recent years as a result of the identification of various forms of synthetic a-galactosylceramide (aGalCer) that specifically activate these cells. The current proposal is focused on the identification of modified forms of aGalCer that activate different cytokine patterns when used to stimulate mouse or human iNKT cells. Numerous Th2-cytokine biasing forms of aGalCer have been identified in our ongoing studies, and we propose new synthetic approaches to create additional aGalCer analogues that will include examples with tolerogenic or proinflammatory activities based on cytokine production or other effects. These compounds will be characterized in detail using assay systems to analyze both mouse and human iNKT cell responses to identify those that are most suitable to carry forward into translational studies. Using new monoclonal antibody reagents specific for CD1d/aGalCer complexes, and soluble iNKT cell antigen receptors, we will carry out a range of studies to determine the mechanisms that lead to the stimulation of markedly different patterns of cytokines by various aGalCer analogues. Studies to optimize the adjuvant properties of selected aGalCer analogues in model systems of vaccination are also proposed. These studies will increase our understanding of the mechanisms governing the regulation of the many potential activities of iNKT cells, and will contribute to development of therapeutic applications for glycolipid activators of this T cell subset.

View original record on NIH RePORTER →